Pioneers in genome editing using our proprietary ARCUS® technology to develop potentially curative therapeutics to overcome cancer and cure genetic disease.
Durham, NC
Joined January 2018
- Tweets478
- Following326
- Followers1.6K
- Likes420
Precision BioSciences retweeted
As version 1.0 genome engineering begins to show promise for patients, we have to look around the corner to imagine what's next. Pleased to announce this collaboration with @PrecisionBioSci to explore biotechnology potentially enabling in vivo editing.
endpts.com/in-pursuit-of-acc…
Precision BioSciences retweeted
June is #NationalCancerSurvivorsMonth. Join us as we #CelebrateSurvivorship with #CancerSurvivorStories all month long. cancercontrol.cancer.gov/ocs…
Precision BioSciences retweeted
Today is #WorldCancerResearchDay.
This is a great time to think about how our work in #CancerResearch can help end cancer as we know it worldwide, particularly for low- and middle-income countries, where #CancerDisparities are often intensified.
Precision BioSciences retweeted
Durham-based #geneediting company @PrecisionBioSci has inked a deal with gene editing company iECURE to advance one of Precision’s drug candidates into Phase 1 clinical studies. bit.ly/3hzApfX
Precision BioSciences retweeted
Upenn's gene therapy leader Jim Wilson launched his 3rd company in 3 years this morning. His new startup, iECURE, will develop gene editing therapies for severe pediatric liver diseases, including OTC deficiency. More in my story for @cenmag cen.acs.org/pharmaceuticals/…
Precision BioSciences retweeted
iECURE’s CEO tells me Wilson tried several gene editing technologies and found that tech from @PrecisionBioSci worked best for this gene insertion. iECURE licensed rights to use Precision’s tech for 4 liver diseases. Precision keeps rights for all other indications. $DTIL
Precision BioSciences retweeted
Our collaborators at @uofl presented a more updated data set at ARVO this year showing that the ERG effects were durable through the latest time points at day 300, and they also saw positive morphological changes in the retina/rods 👍 Here's the release:
businesswire.com/news/home/2…
Precision BioSciences retweeted
Great article on @PrecisionBioSci "One-step gene-editing technique opens door to safe, effective off-the-shelf CAR T cells"
"I jokingly call it #ARCUS CRISPR 2.0" -Dr. Shah 0191 Lead Investigator
healio.com/news/hematology-o…
Precision BioSciences retweeted
“The future is going to be in gene editing,” says Bijal D. Shah, MD, @MoffittNews in our latest feature on gene-editing techniques to produce off-the-shelf #CARTcells bit.ly/2X6sXS2 #ARCUS @PrecisionBioSci
Precision BioSciences retweeted
Great read from @GoHealio for anyone interested in what’s next for #GeneEditing, including an oncologist's explanation of how a simpler, more compact editing tool (ARCUS, aka #CRISPR 2.0) improves off-the-shelf CAR T production bit.ly/3jF3RBC $DTIL
Precision BioSciences retweeted
Derek Jantz (@PrecisionBioSci's CSO) is one of the best scientific storytellers out there. Great discussion here about the history of #GeneEditing, how it works, and how Precision is using #ARCUS with @LillyPad to approach a treatment for Duchenne Muscular Dystrophy.
$DTIL #DMD
Listen to the latest Elixir Factor Podcast for a great discussion on the potential of #GeneEditing to fight rare diseases such as Duchenne. Our CSO Derek Jantz joins host @JoPeKim, patients/advocates from @CureDuchenne & leading scientists from @LillyPad. soundcloud.com/user-45737531…
Precision BioSciences retweeted
Big week for Precision - putting 2+ years of allo CAR T clinical learnings to work by initiating dosing w/advanced versions of both their anti-BCMA (+nirogacestat) and anti-CD19 (+cloaking for durability). Congrats! #CART #oncology #stealthcell $DTIL
It’s been an exciting week! We’re pleased to announce the first patient dosed in our Phase 1 clinical trial with PBCAR19B, an immune-evading allogeneic CAR T stealth cell candidate for patients with relapsed/refractory (R/R) NHL. Read more here: investor.precisionbioscience…
Precision BioSciences retweeted
A Durham company's interim clinical trial results for a leukemia treatment have company executives optimistic about the treatment's future. bizjournals.com/triangle/new…
Precision BioSciences retweeted
Using gene editing to improve CAR T. Dr. Bijal Shah presents initial results of a novel allogeneic CAR T product that incorporates gene editing technology at #ASCO21
Precision BioSciences retweeted
Thoughtful GTx discussion with a nice mention for $DTIL by Jim Wilson (~15min). Comparing ARCUS to #CRISPR for in vivo #GeneEditing: “It simply just worked a lot better.” On demand bit.ly/3bAAqgD
Happening Now! The latest episode of GEN Live--The State of Gene Therapy. Join in now: genengnews.com/resources/web… #GeneTherapy #geneticdisorders
Precision BioSciences retweeted
Happening Now! The latest episode of GEN Live--The State of Gene Therapy. Join in now: genengnews.com/resources/web… #GeneTherapy #geneticdisorders
Precision BioSciences retweeted
On Thursday at 6:00PM ET @cngarabedian and I have put together an all-star panel on CH to talk cell & gene therapy.
@BrianSkorney - Baird
Caroline Stout - EcoR1
@ChrisHeery - Precision Biosciences
@PDRennert - Aleta BioTherapeutics
joinclubhouse.com/event/Gxo2…
Precision BioSciences retweeted
Aleta Bio will also be represented at the Oncology Cell Therapy Summit where I will join a town hall discussion on the challenges posed by Tumor Microenvironments - with @ChrisHeery from Precision and Christina Coughlin from Rubius
events.kisacoresearch.com/oc…
Precision BioSciences retweeted
Thanks @mlazaru for calling out the 4 year NHP data from Jim Wilson using @PrecisionBioSci ARCUS platform. 4 years: >90% reduction in PCSK9 and >50% reduction in LDL $DTIL Now we’re on the move to even more difficult targets, including #DMD – at Westfield, NJ
$DTIL been editing monkeys in PCSK9 for 4 years already, program with jim wilson. Arcus Editing has advantage over CRISPR.
